Skip to Main Content

Pancreatic cancer is hard to detect early and notoriously resistant to treatment, making it the deadliest type of major cancer. Rafael Pharmaceuticals, a small drug maker backed by a telecom billionaire, hopes to deliver better news for patients and investors with the readout of a large clinical trial within the next two months.

It’s an inordinately risky challenge for Rafael, but with a giant payoff if successful. Here are six things to know about the company and its drug, devimistat, before Phase 3 pancreatic cancer study results are announced.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment